Roth Capital Upgrades Iradimed Corp to Buy

By Ryan Adsit

Roth Capital analyst Chris Lewis upgraded Iradimed Corp (NASDAQ: IRMD) to Buy today. The company’s shares closed on Friday at $9.80, close to its 52-week high of $19.73.

According to, Lewis is a 4-star analyst with an average return of 7.7% and a 53.1% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Cogentix Medical Inc, Trinity Biotech Plc, and Lemaitre Vascular.

Iradimed Corp has an analyst consensus of Moderate Buy.

Iradimed Corp’s market cap is currently $105.3M and has a P/E ratio of 24.5. The company has a book value ratio of 3.2894.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IRadimed Corp. engages in the development, manufacture, market, and distribution of magnetic resonance imaging compatible products and non-magnetic intravenous infusion pump systems for use by hospitals and acute care facilities. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.